Presbyopia-Correcting ICL

About STAAR Surgical

STAAR Surgical's mission is to design, develop, manufacture, and market implantable lenses that reduce or eliminate dependence on glasses and contact lenses. The company has achieved significant commercial traction, surpassing 4 million ICL units sold worldwide and operating in over 75 countries, which underscores the broad market acceptance of its technology. Its strategy centers on leveraging its proprietary Collamer material and vertical integration to drive innovation, expand indications, and capitalize on the global shift towards premium, lens-based refractive solutions. STAAR is a revenue-generating, publicly traded pure-play in the ophthalmology device sector.

Therapeutic Areas

Other Presbyopia Drugs